Loss of Trp53 gene promotes tumor growth and immune suppression in ovarian cancer
“These results highlight potential mechanisms by which loss of p53 function contributes to an immunosuppressive microenvironment in HGSC, and provide insight into the role of ovarian and peritoneal microenvironments in regulating HGSC..."
2025-09-24
(Press-News.org)
“These results highlight potential mechanisms by which loss of p53 function contributes to an immunosuppressive microenvironment in HGSC, and provide insight into the role of ovarian and peritoneal microenvironments in regulating HGSC cell-intrinsic inflammatory signaling.”
BUFFALO, NY – September 24, 2025 – A new research paper was published in Volume 16 of Oncotarget on September 22, 2025, titled “Loss of Trp53 results in a hypoactive T cell phenotype accompanied by reduced pro-inflammatory signaling in a syngeneic orthotopic mouse model of ovarian high-grade serous carcinoma.”
In this study, led by first author Jacob Haagsma and corresponding author Trevor G. Shepherd from the Verspeeten Family Cancer Centre and Western University, Canada, researchers investigated how the loss of Trp53 – a critical tumor suppressor gene – affects immune responses in ovarian cancer. The team found that deleting Trp53 led to more aggressive tumor growth and a weaker immune response. These findings help explain why some ovarian tumors may be resistant to immunotherapy and point to new ways to improve treatment.
High-grade serous ovarian carcinoma (HGSC) is a deadly cancer that is often diagnosed at a late stage. Immunotherapy, which enhances the body’s immune system to fight cancer, has shown limited effectiveness in treating this type of cancer. To better understand why, the researchers developed a mouse model that closely mimics human HGSC. They injected ovarian epithelial cells, with and without Trp53, into the fallopian tubes, the origin site of most ovarian cancers.
“In this study, we developed a syngeneic model reflecting both the site of origin and the genotype of early HGSC disease by deleting Trp53 in mouse oviductal epithelial (OVE) cells.”
Mice injected with cells lacking Trp53 developed faster-growing and more invasive tumors, reflecting how the disease typically progresses in humans. These tumors also had fewer active T cells, which are immune cells responsible for attacking cancer. Moreover, the T cells that were present appeared less capable of responding to the tumor, creating an immune environment that allowed cancer to grow uncontrolled.
Further analysis revealed that tumor cells without Trp53 had reduced activity in genes related to inflammation. These changes were associated with lower levels of key proteins that normally help immune cells detect and attack tumor cells. When the researchers collected tumor cells from the abdominal fluid of the mice—a condition that simulates advanced-stage disease—they observed even lower immune signaling than before. This suggests that as the tumor spreads, it becomes better at evading the immune system.
This study highlights how early genetic mutations can shape the interaction between tumors and the immune system. In particular, the loss of Trp53 appears to trigger a chain of events that weakens immune surveillance and accelerates tumor progression. These findings emphasize the need to consider both genetic mutations and the tumor environment when designing immunotherapies for ovarian cancer. Understanding how genes like Trp53 influence immune behavior may lead to more effective treatments and help identify which patients are most likely to benefit from immunotherapy.
DOI: https://doi.org/10.18632/oncotarget.28768
Correspondence to: Trevor G. Shepherd – tshephe6@uwo.ca
Abstract video: https://www.youtube.com/watch?v=WFQw0psuC3M
Keywords: cancer, high-grade serous ovarian carcinoma, orthotopic models, inflammation, microenvironment
Click here to sign up for free Altmetric alerts about this article.
About Oncotarget:
Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.
Oncotarget is indexed and archived by PubMed/Medline, PubMed Central, Scopus, EMBASE, META (Chan Zuckerberg Initiative) (2018-2022), and Dimensions (Digital Science).
To learn more about Oncotarget, visit Oncotarget.com and connect with us on social media:
X
Facebook
YouTube
Instagram
LinkedIn
Pinterest
Spotify, and available wherever you listen to podcasts
Click here to subscribe to Oncotarget publication updates.
For media inquiries, please contact media@impactjournals.com.
END
ELSE PRESS RELEASES FROM THIS DATE:
2025-09-24
For over 100 years, teddy bears have been a hallmark of childhood nurseries, ubiquitously embedded in our early memories and rarely the object of deep scrutiny. However, according a recent article in BioScience by Dr. Nicolas Mouquet (CRNS) and colleagues, the humble teddy bear is much more than a mere plaything. Instead, the authors suggest that the beloved plushes play a pivotal role in our early conception of nature, potentially shaping the ways we interact with the natural world throughout our lives.
...
2025-09-24
Steve Jobs berated his teams. Jack Welch laid off a quarter of his workforce. Still, both are seen as visionary leaders and continue to serve as role models for many. A recent study takes a closer look at the logic and conditions of such leadership approaches. It shows that such radical leadership styles only work under specific circumstances and in some cases do more harm than good.
The study Annealing as an Alternative Mechanism for Management was authored by Matthew S. Bothner, professor of strategy ...
2025-09-24
The 12th Heidelberg Laureate Forum (HLF) has come to a close. This year’s HLF took place from September 14 to 19 and brought together 28 Laureates of the most prestigious prizes in mathematics and computer science as well as 200 of those disciplines’ brightest Young Researchers of the next generation.
The week featured a host of fascinating talks, panels and interactive formats where some of the timeliest issues relating to mathematics and computer science were discussed, with a particular attention paid to the effects of AI on a host of issues. The program included a talk by Richard S. Sutton (2024 ACM A.M. Turing Award), pondering “The Future of Artificial Intelligence,” ...
2025-09-24
Scientists at Université de Montréal’s affiliated hospital research centre (CRCHUM) are testing out a mobile application to help young adults who have a first episode of psychosis to support safer cannabis consumption.
The nationwide clinical trial, a first in Canada, is led by Université de Montréal psychiatry and addictology professor Didier Jutras-Aswad, a researcher at CRCHUM.
Called CHAMPS (Cannabis Harm-reducing App to Manage Practices Safely), the pilot study is described in an article published in the August issue of Psychiatry Research.
The new study is backed by $800,000 in funding ...
2025-09-24
New York, 24 September 2025 – The International Telecommunication Union (ITU) – the United Nations agency for digital technologies – Google, and musician, tech founder and philanthropist will.i.am have launched an initiative to bring artificial intelligence and robotics training to students across Africa.
Announced during the Digital@UNGA Anchor Event at the UN General Assembly, the programme combines hands-on AI and robotics training for young people in underserved communities, including in those countries where the ...
2025-09-24
Researchers at University of California San Diego, part of the national HEALthy Brain and Child Development (HBCD) Study Consortium, have announced the first data release from this landmark study, providing scientists around the world with new ways to answer critical questions about human brain development in early childhood. This inaugural data release includes comprehensive biomedical and behavioral data from more than 1,400 pregnant women and their children, collected across three early developmental stages from birth through nine months of age.
"This ...
2025-09-24
What causes us to sleep? The answer may lie not only in our brains, but in their complex interplay with the micro-organisms spawned in our intestines.
New research from Washington State University suggests a new paradigm in understanding sleep, demonstrating that a substance in the mesh-like walls of bacteria, known as peptidoglycan, is naturally present in the brains of mice and closely aligned with the sleep cycle.
Those findings serve to update a broader hypothesis that has been in development at WSU for years—proposing that sleep arises from communication between the body’s sleep regulatory systems and the multitude of microbes living inside us.
“This ...
2025-09-24
About 12 million adults in the United States are affected by PTSD, impacting between 4% and 8% of the adult population – and up to 30% of military personnel and veterans. Strikingly, 63% of veterans with post-traumatic stress disorder also suffer from alcohol use disorder (AUD) and/or chronic pain. These conditions frequently overlap, with individuals who have AUD or chronic pain often also experiencing PTSD.
When these disorders co-occur, they tend to worsen one another, making effective treatment significantly more challenging. Currently, no approved ...
2025-09-24
Researchers from University of California San Diego School of Medicine have found that testing for lipoprotein(a) — a genetic risk factor for heart disease — remains uncommon in the United States, despite modest increases over the past decade. The findings were published on Sept. 26, 2025 in the Journal of the American College of Cardiology: Advances.
Lipoprotein(a) — or Lp(a) — is a type of cholesterol particle in the blood. Elevated levels are strongly linked to a higher risk of heart attack, stroke and aortic valve disease. Roughly 20% of the U.S. population has elevated Lp(a), yet testing rates have historically been low.
In the ...
2025-09-24
WASHINGTON (September 24, 2025) — Cardiovascular diseases (CVD) remain the leading cause of disease burden , causing one in three deaths worldwide as a result of population growth, population aging and exposure to a broad range of risks, including increasing rates of obesity and diabetes, according to the latest Global Burden of Disease (GBD) Study special report published today in JACC, the flagship journal of the American College of Cardiology.
“This research provides countries with ...
LAST 30 PRESS RELEASES:
[Press-News.org] Loss of Trp53 gene promotes tumor growth and immune suppression in ovarian cancer
“These results highlight potential mechanisms by which loss of p53 function contributes to an immunosuppressive microenvironment in HGSC, and provide insight into the role of ovarian and peritoneal microenvironments in regulating HGSC..."
